Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease: The POPEYE Randomized Controlled Clinical Trial.
Bevers N, Van de Vijver E, Aliu A, Rezazadeh Ardabili A, Rosias P, Stapelbroek J, Bertrams Maartens IA, van de Feen C, Escher H, Oudshoorn A, Teklenburg S, Vande Velde S, Winkens B, Raijmakers M, Vreugdenhil A, Pierik MJ, van Rheenen PF. Bevers N, et al. Among authors: stapelbroek j. J Pediatr. 2023 May;256:113-119.e4. doi: 10.1016/j.jpeds.2022.12.016. Epub 2022 Dec 21. J Pediatr. 2023. PMID: 36563900 Free article. Clinical Trial.
Fatigue and Physical Activity Patterns in Children With Inflammatory Bowel Disease.
Bevers N, Van de Vijver E, Hanssen A, Aliu A, Vande Velde S, Roelant E, Rezazadeh Ardabili A, Rosias P, Stapelbroek J, Maartens IB, van de Feen C, Escher J, Oudshoorn A, Teklenburg-Roord S, Vreugdenhil A, Pierik M, van Rheenen P. Bevers N, et al. Among authors: stapelbroek j. J Pediatr Gastroenterol Nutr. 2023 Nov 1;77(5):628-633. doi: 10.1097/MPG.0000000000003905. Epub 2023 Jul 26. J Pediatr Gastroenterol Nutr. 2023. PMID: 37494540
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk SA, Jongsma MME, Hoeven BM, Cozijnsen MA, van Pieterson M, de Meij TGJ, Norbruis OF, Groeneweg M, Wolters VM, van Wering H, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg S, Rizopoulos D, Poley MJ, Escher JC, de Ridder L. Vuijk SA, et al. Among authors: stapelbroek j. Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.18000. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 38644588
Safety of Thioguanine in Pediatric Inflammatory Bowel Disease: A Multi-Center Case Series.
Bayoumy AB, Jagt JZ, van Wering HM, de Ridder L, Hummel T, Wolters VM, Stapelbroek J, Benninga MA, Mulder CJJ, de Boer NKH, de Meij TGJ; Kids with Crohn’s, Colitis (KiCC) Working Group for Collaborative Paediatric IBD Research in the Netherlands. Bayoumy AB, et al. Among authors: stapelbroek j. J Pediatr Gastroenterol Nutr. 2022 Dec 1;75(6):e111-e115. doi: 10.1097/MPG.0000000000003621. Epub 2022 Sep 20. J Pediatr Gastroenterol Nutr. 2022. PMID: 36136124 Free PMC article.
Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study.
Gilissen LPL, Heinen SGH, Rijpma-Jacobs L, Schoon E, Schreuder RM, Wensing AM, van der Ende-van Loon MCM, Bloemen JG, Stapelbroek JM, Stronkhorst A. Gilissen LPL, et al. Among authors: stapelbroek jm. Clin Exp Med. 2022 Aug;22(3):465-476. doi: 10.1007/s10238-021-00755-3. Epub 2021 Sep 20. Clin Exp Med. 2022. PMID: 34542781 Free PMC article.
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Jongsma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, Norbruis OF, Wolters VM, van Wering HM, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg-Roord STA, Schreurs MWJ, Rizopoulos D, Doukas M, Escher JC, Samsom JN, de Ridder L. Jongsma MME, et al. Among authors: stapelbroek j. Gut. 2022 Jan;71(1):34-42. doi: 10.1136/gutjnl-2020-322339. Epub 2020 Dec 31. Gut. 2022. PMID: 33384335 Free PMC article. Clinical Trial.
Loss of syntaxin 3 causes variant microvillus inclusion disease.
Wiegerinck CL, Janecke AR, Schneeberger K, Vogel GF, van Haaften-Visser DY, Escher JC, Adam R, Thöni CE, Pfaller K, Jordan AJ, Weis CA, Nijman IJ, Monroe GR, van Hasselt PM, Cutz E, Klumperman J, Clevers H, Nieuwenhuis EE, Houwen RH, van Haaften G, Hess MW, Huber LA, Stapelbroek JM, Müller T, Middendorp S. Wiegerinck CL, et al. Among authors: stapelbroek jm. Gastroenterology. 2014 Jul;147(1):65-68.e10. doi: 10.1053/j.gastro.2014.04.002. Epub 2014 Apr 12. Gastroenterology. 2014. PMID: 24726755
Mutational analysis of ATP8B1 in patients with chronic pancreatitis.
van der Woerd WL, van Haaften-Visser DY, van de Graaf SF, Férec C, Masson E, Stapelbroek JM, Bugert P, Witt H, Houwen RH. van der Woerd WL, et al. Among authors: stapelbroek jm. PLoS One. 2013 Nov 19;8(11):e80553. doi: 10.1371/journal.pone.0080553. eCollection 2013. PLoS One. 2013. PMID: 24260417 Free PMC article.
Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.
Nijmeijer RM, Gadaleta RM, van Mil SW, van Bodegraven AA, Crusius JB, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, Verspaget HW, Weersma RK, van der Woude CJ, Stapelbroek JM, Schipper ME, Wijmenga C, van Erpecum KJ, Oldenburg B; Dutch Initiative on Crohn, Colitis (ICC). Nijmeijer RM, et al. Among authors: stapelbroek jm. PLoS One. 2011;6(8):e23745. doi: 10.1371/journal.pone.0023745. Epub 2011 Aug 22. PLoS One. 2011. PMID: 21887309 Free PMC article.
20 results